KEYTRUDA (pembrolizumab), anti-PD1 antibody

Minor clinical added value in first-line treatment of advanced melanoma

• KEYTRUDA has marketing authorisation as monotherapy in the treatment of adults with advanced (unresectable or metastatic) melanoma.
• In the absence of BRAF mutation, like nivolumab (OPDIVO), it is recommended as a first-line treatment.
• If there is BRAF mutation, like nivolumab (OPDIVO), its role as an alternative to targeted therapies is currently debated, especially the patient profile that could receive one of these two treatments as a first line.

Avis économique

Ce produit a fait l'objet d'un avis du collège de la Haute Autorité de santé le 16 mars 2016 sur l'efficience de la prise en charge par l'assurance maladie de la spécialité KEYTRUDA (pembrolizumab) dans le traitement du mélanome avancé (non résécable ou métastatique).

> KEYTRUDA - Avis n° 2016.0027(pdf)